title: [Effect of invigorating spleen and detoxification decoction on MHC I/MHC II in spleen-deficiency liver cancer rats survival].
abstract: OBJECTIVE
  To explore that Invigorating Spleen and Detoxification Decoction (ISD) enhanced the survival of spleen-deficiency liver cancer rats and the effect on major histocompatibility complex I (MHC I) and major histocompatibility complex II (MHC II).
  
  
  METHODS
  105 male Wistar rats were randomly divided into blank control group, liver cancer model group, spleen-deficiency model group, spleen-deficiency liver cancer model group, Thymopentin group and spleen-deficiency liver cancer model groups treated by low and high-concentration ISD for modeling and intervention. Recorded the animals' weight, survival time, moribund state and cachexia score of liver cancer rats, and collected specimens in the experiment. Immunohistochemistry and Western blot were used to detect MHC I/MHC II expression in liver tissue and liver cancer tissue.
  
  
  RESULTS
  The cumulative survival of high concentration ISD group and Thymopentin group were higher than that of the other groups (P < 0.05), and whose cachexia score were lower than the rest (P < 0.05). In the spleen-deficiency liver cancer model groups, MHC I expression in liver tissue was higher than that in liver cancer tissue, both in these two tissues, expression of high-concentration ISD group was the strongest (P < 0.01). MHC II expression in liver cancer tissue was stronger than that in liver tissue, expression of high-concentration ISD group was the strongest in liver tissue, but in liver cancer tissue, the spleen-deficiency liver cancer model group was the strongest (P < 0.01).
  
  
  CONCLUSIONS
  ISD can significantly decrease the progression of cachexia caused by transplantable tumor and prolong the survival time, the effect may be related to increasing MHC I/MHC II expression.
authors.forename: Yu-Long
authors.initials: YL
authors.lastname: Li
authors.forename: Bao-Guo
authors.initials: BG
authors.lastname: Sun
authors.forename: Ting
authors.initials: T
authors.lastname: Xiang
authors.forename: Ze-Xiong
authors.initials: ZX
authors.lastname: Chen
authors.forename: Shi-Jun
authors.initials: SJ
authors.lastname: Zhang
mesh_terms: D000818:Animals; D002100:Cachexia / Q000209:etiology / Q000473:pathology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D000949:Histocompatibility Antigens Class II / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000187:drug effects / Q000503:physiopathology*; D016019:Survival Analysis; D015854:Up-Regulation
chemical_list: D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II